Literature DB >> 10703970

Simultaneous determination of benazepril hydrochloride and hydrochlorothiazide by micro-bore liquid chromatography.

I E Panderi1, M Parissi-Poulou.   

Abstract

A micro-bore liquid chromatographic method was developed for the simultaneous determination of benazepril hydrochloride and hydrochlorothiazide in pharmaceutical dosage forms. The use of a BDS C-18 micro-bore analytical column, results in substantial reduction in solvent consumption and increased sensitivity. The mobile phase consisted of a mixture of 0.025 M sodium dihydrogen phosphate (pH 4.8) and acetonitrile (55:45, v/v), pumped at a flow rate of 0.40 ml min(-1). Detection was set at 250 nm using an ultraviolet detector. Calibration graphs are linear (r better than 0.9991, n = 5), in concentration range 5.0-20.0 microg ml(-1) for benazepril hydrochloride and 6.2-25.0 microg ml(-1) for hydrochlorothiazide. The intra- and interday R.S.D. values were <1.25% (n = 5), while the relative percentage error (Er) was <0.9% (n = 5). The detection limits attained according to IUPAC definition were 0.88 and 0.58 microg ml(-1) for benazepril hydrochloride and hydrochlorothiazide, respectively. The method was applied in the quality control of commercial tablets and content uniformity test and proved to be suitable for rapid and reliable quality control.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10703970     DOI: 10.1016/s0731-7085(99)00195-8

Source DB:  PubMed          Journal:  J Pharm Biomed Anal        ISSN: 0731-7085            Impact factor:   3.935


  2 in total

1.  Spectrofluorimetric assessment of hydrochlorothiazide using optical sensor nano-composite terbium ion doped in sol-gel matrix.

Authors:  A O Youssef
Journal:  J Fluoresc       Date:  2011-12-21       Impact factor: 2.217

2.  Application of narrow-bore HPLC columns in rapid determination of sildenafil citrate in its pharmaceutical dosage forms.

Authors:  Razieh Ghodsi; Farzad Kobarfard; Sayyed Abbas Tabatabai
Journal:  Iran J Pharm Res       Date:  2012       Impact factor: 1.696

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.